Skip to main content
. 2022 Nov 22;9(12):ofac632. doi: 10.1093/ofid/ofac632

Figure 1.

Figure 1.

Admissions, mortality, and treatments for COVID-19 in the first, second, third, and fourth waves in the Netherlands. A, Admissions, mortality, and novel antiviral and immunosuppressive treatments for COVID-19 in the first, second, third, and fourth waves in the Netherlands. Between February 27, 2020, and December 31, 2021, 89 110 patients with confirmed COVID-19 were admitted to the ward and 16 590 patients to the ICU in the Netherlands; 10 317 COVID-19 patients died on the ward and 4511 in the ICU. In this time period, 6 novel drug treatment modalities were implemented through national guidelines [10], either as standard or optional care for patients hospitalized because of COVID-19. Gray bars: included in national treatment guidelines as optional care; red bars: included as standard care. aDexamethasone was first only recommended for ICU patients, since September 29, 2020, also for ward patients. bIL-6 antagonists were first only recommended for ICU patients, since March 9, 2021, also for ward patients. cCasirivimab/imdevimab was recommended until December 23, 2021; sotrovimab was recommended since December 23, 2021. B, Administration of novel antiviral and immunosuppressive treatments for hospitalized COVID-19 in the first, second, third, and fourth waves in the Netherlands. The percentage of patients included in the COVIDPredict trial treated with the 6 novel drug treatment modalities implemented through national guidelines in the time period between February 27, 2020, and December 31, 2021. aIncluded dexamethasone, prednisolone, hydrocortisone, and methylprednisolone. Abbreviations: COVID-19, coronavirus disease 2019; ICU, intensive care unit; IL, interleukin; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.